Engineering of a functional human NADH-dependent cytochrome P450 system.

A functional human NADH-dependent cytochrome P450 system has been developed by altering the cofactor preference of human NADPH cytochrome P450 reductase (CPR), the redox partner for P450s. This has been achieved by a single amino acid change of the conserved aromatic amino acid Trp-676, which covers the re-side of the FAD isoalloxazine ring in the nicotinamide-binding site. Of the mutations made, the substitution of Trp-676 with alanine (W676A) resulted in a functional NADH-dependent enzyme, which catalyzed the reduction of cytochrome c and ferricyanide as well as facilitated the metabolism of 7-ethoxyresorufin by CYP1A2. Kinetic analysis measuring cytochrome c activity revealed that the NADH-dependent k(cat) of W676A is equivalent (90%) to the NADPH-dependent k(cat) of the wild-type enzyme, with W676A having an approximately 1,000-fold higher specificity for NADH. The apparent K(M)(NADPH) and K(M)(NADH) values of W676A are 80- and 150-fold decreased, respectively. In accordance with structural data, which show a bipartite binding mode of NADPH, substitution of Trp-676 does not affect 2'-AMP binding as seen by the inhibition of both wild-type CPR and the W676A mutant. Furthermore, NADPH was a potent inhibitor of the W676A NADH-dependent cytochrome c reduction and CYP1A2 activity. Overall, the results show that Trp-676 of human CPR plays a major role in cofactor discrimination, and substitution of this conserved aromatic residue with alanine results in an efficient NADH-dependent cytochrome P450 system.

[1]  N. Bachur,et al.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Karplus,et al.  A productive NADP+ binding mode of ferredoxin–NADP + reductase revealed by protein engineering and crystallographic studies , 1999, Nature Structural Biology.

[3]  C. C. Correll,et al.  Phthalate dioxygenase reductase: a modular structure for electron transfer from pyridine nucleotides to [2Fe-2S]. , 1992, Science.

[4]  P. Karplus,et al.  Crystallographic analysis of the binding of NADPH, NADPH fragments, and NADPH analogues to glutathione reductase. , 1988, Biochemistry.

[5]  F. Oesch,et al.  Characterization, localization and regulation of a novel phenobarbital-inducible form of cytochrome P450, compared with three further P450-isoenzymes, NADPH P450-reductase, glutathione transferases and microsomal epoxide hydrolase. , 1984, Carcinogenesis.

[6]  F. Arnold,et al.  Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation , 1999, Nature.

[7]  S. Snyder,et al.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase , 1991, Nature.

[8]  J. Abel,et al.  Effect of transforming growth factor-β1 on cytochrome P450 expression: inhibition of CYP1 mRNA and protein expression in primary rat hepatocytes , 2000, Archives of Toxicology.

[9]  M. J. Coon,et al.  Purified liver microsomal NADPH-cytochrome P-450 reductase. Spectral characterization of oxidation-reduction states. , 1978, The Journal of biological chemistry.

[10]  C. Wolf,et al.  Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli , 1996, FEBS letters.

[11]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[12]  M. J. Coon,et al.  Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P-450 reductase. , 1978, The Journal of biological chemistry.

[13]  D. Waxman,et al.  Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. , 1998, Cancer research.

[14]  R. T. Miller,et al.  Rapid kinetic studies of electron transfer in the three isoforms of nitric oxide synthase. , 1999, Biochemical and biophysical research communications.

[15]  P. Karplus,et al.  Competition between C-terminal Tyrosine and Nicotinamide Modulates Pyridine Nucleotide Affinity and Specificity in Plant Ferredoxin-NADP+ Reductase* , 2000, The Journal of Biological Chemistry.

[16]  C. W. Fisher,et al.  The use of electrochemistry for the synthesis of 17α-hydroxyprogesterone by a fusion protein containing P450c17 , 1996 .

[17]  P. Ortiz de Montellano,et al.  Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. , 1999, Cancer research.

[18]  D. Sem,et al.  Kinetic mechanism for the model reaction of NADPH-cytochrome P450 oxidoreductase with cytochrome c. , 1994, Biochemistry.

[19]  Aaron D. Wilson,et al.  Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Wolf,et al.  Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Karplus,et al.  Atomic structure of ferredoxin-NADP+ reductase: prototype for a structurally novel flavoenzyme family. , 1991, Science.

[22]  R D Schmid,et al.  Electrochemical reduction of flavocytochromes 2B4 and 1A2 and their catalytic activity. , 2000, Archives of biochemistry and biophysics.

[23]  C. Wolf,et al.  A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. , 1997, Archives of biochemistry and biophysics.

[24]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[25]  W. Pryor.  Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[26]  D. Sem,et al.  Enzyme-substrate binding interactions of NADPH-cytochrome P-450 oxidoreductase characterized with pH and alternate substrate/inhibitor studies. , 1993, Biochemistry.

[27]  H. Strobel,et al.  Preparation of homogeneous NADPH-cytochrome P-450 reductase from rat liver. , 1975, Biochemical and biophysical research communications.

[28]  Y. Yasukochi,et al.  Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. , 1976, The Journal of biological chemistry.

[29]  C. Wolf,et al.  Cloning and Characterization of a Novel Human Dual Flavin Reductase* , 2000, The Journal of Biological Chemistry.

[30]  Denis Pompon,et al.  Self-sufficient biosynthesis of pregnenolone and progesterone in engineered yeast , 1998, Nature Biotechnology.

[31]  F. Guengerich,et al.  Expression of drug-metabolizing enzymes. , 1997, Current opinion in biotechnology.

[32]  C. Wolf,et al.  Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison. , 1999, Drug metabolism reviews.

[33]  P. Workman,et al.  The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. , 1992, Biochemical pharmacology.

[34]  B. Masters,et al.  Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Sem,et al.  Interaction with arginine 597 of NADPH-cytochrome P-450 oxidoreductase is a primary source of the uniform binding energy used to discriminate between NADPH and NADH. , 1993, Biochemistry.

[36]  P. Karplus,et al.  Structural prototypes for an extended family of flavoprotein reductases: Comparison of phthalate dioxygenase reductase with ferredoxin reductase and ferredoxin , 1993, Protein science : a publication of the Protein Society.

[37]  C L Crespi,et al.  The use of heterologously expressed drug metabolizing enzymes--state of the art and prospects for the future. , 1999, Pharmacology & therapeutics.

[38]  E. Werner,et al.  Determination of nitric oxide synthase cofactors: heme, FAD, FMN, and tetrahydrobiopterin. , 1996, Methods in enzymology.